Study on joint damage in hemophilia A patients using emicizumab
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial uses ultrasound to check if healthy joints in people with hemophilia A develop damage while being treated with emicizumab (Hemlibra). It looks at elbows, knees, and ankles over time to see if the medicine prevents joint problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hemophilia A.
- You are currently taking emicizumab (Hemlibra) as part of your regular care.
- You are at least 10 years old.
- You have at least one joint (elbow, knee, or ankle) that looks healthy on an ultrasound (no damage).
- You have not had any bleeding into those same joints since starting emicizumab.
- You can understand and complete study tasks like interviews or questionnaires.
- You (or your parent/guardian if you are a minor) agree to join the study and sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at chronic pain in people with severe hemophilia A. It aims to understand pain better through questionnaires and joint health checks.
This study uses ultrasound to check the health of joints in adults with mild hemophilia. It may help doctors understand how to better care for people with this condition.
This trial tests emicizumab, a medicine given under the skin, to see how it works in children with hemophilia A. It aims to help control bleeding, no matter if they have inhibitors or not.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study uses ultrasound to check if thickened joint lining (synovium) in people with severe hemophilia is a sign of active inflammation or just a harmless leftover. It may help doctors decide whether to treat or watch these joints.
This study looks at how many adults with moderate or severe hemophilia A have inflammation in their joints (synovitis). It aims to better understand joint health in people with hemophilia A, including those with inhibitors or joint replacements.
Hear when a new Hemophilia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.